Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 2, 2020
- Pharmaceutical Technology-04-02-2020
- Volume 44
- Issue 4
Quaternary Diaphragm Pump
The QF2500 Quaternary Diaphragm Pump from Quattroflow, part of PSG, a Dover company, extends the company’s range of pumps.
The QF2500 Quaternary Diaphragm Pump from Quattroflow, part of PSG, a Dover company, extends the company’s range of pumps. The pump has a maximum flow rate of 2500 lph (660 gph) to meet the needs of chromatography, tangential flow filtration, virus filtration, sterile filtration, and depth filtration applications.
The device features a new pump chamber, a self-draining design, a 125:1 turndown ratio, high flow stability, linear flow performance, and clean-in-place capabilities. Users can also add on a power box, diaphragm sensor, and PID pressure controller. With the addition of this pump, Quattro flow pumps are now available in eight sizes ranging from 0.06 to 16,000 lph (0.02 to 4227 gph). The design and pumping principle result in dry running, low pulsation, self-priming, and minimal particle generation.
Articles in this issue
over 6 years ago
Biosimilars Poised for Gains in US Marketover 6 years ago
Critical Knowledge for Preparing Auditsover 6 years ago
Can Vaccine Development Be Safely Accelerated?over 6 years ago
Supercritical Fluid Chromatography Systemover 6 years ago
Custom-Built Heated Storage Vesselover 6 years ago
Well Plates and Cartridges for Liquid Extractionover 6 years ago
Alternative Cleaning Validation Methods for Biologicsover 6 years ago
Pharma’s Leadership Role in a PandemicRelated to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.